论文部分内容阅读
目的探讨长效二氢吡啶类(DHPS)降压药物氨氯地平、阿折地平对高血压病患者血浆炎性介质超敏C反应蛋白(hs-CRP)、1-型组织基质金属蛋白酶抑制物(TIMP-1)浓度的影响。方法将55例高血压病患者随机双盲分为氨氯地平组(28例)和阿折地平组(27例),2组经过2周的药物洗脱期后,分别给予8周的氨氯地平(5～10mg/d)或阿折地平(8～16mg/d)治疗,在治疗前后对血压情况及hs-CRP、TIMP-1进行监测。结果2组患者治疗后收缩压和舒张压均显著下降,血压达标率分别为67.9%和70.4%。氨氯地平组hs-CRP治疗前后分别为(4.48±4.64)mg/L、(1.49±1.62)mg/L,阿折地平组分别为(3.44±1.58)mg/L、(1.19±0.95)mg/L;氨氯地平组TIMP-1治疗前后分别为(78.31±46.21)ng/ml、(55.12±31.17)ng/ml,阿折地平组分别为(73.89±27.69)ng/ml、(45.69±16.87)ng/ml,均显著下降(P均<0.05)。结论氨氯地平和阿折地平对高血压病患者在有效降压的同时,均能降低血浆中炎性介质hs-CRP、TIMP-1的含量,可能在一定程度上降低高血压靶器官的损伤。
Objective To investigate the effects of long-acting dihydropyridine (DHPS) antihypertensive drugs, such as amlodipine and aztrendin, on plasma levels of hs-CRP and 1-type tissue inhibitor of matrix metalloproteinase (TIMP-1) concentration. Methods A total of 55 hypertensive patients were randomly divided into amlodipine group (n = 28) and amlodipine group (n = 27). After 2 weeks of drug elution period, (5 ~ 10mg / d) or amlodipine (8 ~ 16mg / d). The blood pressure, hs-CRP and TIMP-1 were monitored before and after treatment. Results After treatment, the systolic and diastolic blood pressures decreased significantly in both groups, with the blood pressure compliance rates of 67.9% and 70.4%, respectively. The levels of hs-CRP in the amlodipine group were (4.48 ± 4.64) mg / L and (1.49 ± 1.62) mg / L respectively before and after treatment with amlodipine and (3.44 ± 1.58) mg / / L, and the levels of TIMP-1 in amlodipine group were (78.31 ± 46.21) ng / ml and (55.12 ± 31.17) ng / ml before and after treatment, 16.87) ng / ml, all decreased significantly (all P <0.05). Conclusion Both amlodipine and aztrendin can effectively decrease the plasma hs-CRP and TIMP-1 levels in patients with essential hypertension while lowering blood pressure and target organ damage to a certain extent .